Evidence map›Paper›PMID 41863598›Full record

ArticleCellular and molecular life sciences : CMLS2026

Schizophrenia risk variants modulate transcription factor binding and gene expression in cortical cell types.

Nathalie Gerstner, Anna S Fröhlich, Natalie Matosin, Elisabeth B Binder, Janine Knauer-Arloth

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nathalie GerstnerMax Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany.ORCID http://orcid.org/0000-0002-3111-5949
Anna S FröhlichMax Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany.
Natalie MatosinCharles Perkins Centre, The University of Sydney, Sydney, Australia.
Elisabeth B BinderMax Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany.
Janine Knauer-ArlothMax Planck Institute of Psychiatry, Department Genes and Environment, Munich, Germany. arloth@psych.mpg.de.ORCID http://orcid.org/0000-0003-3825-4279

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia is a complex neuropsychiatric disorder with a strong genetic component. Genome-wide association studies (GWAS) have identified numerous risk variants, but their functional impact on gene regulation remains largely unknown. A major challenge lies in interpreting the function of non-coding variants, which comprise the majority of GWAS hits, making it difficult to determine their functional consequences, particularly in identifying the target genes and cell types involved. We investigated the disruption and enhancement of transcription factor (TF) binding motifs by schizophrenia-associated GWAS SNPs in 15 cortical cell types of the human brain. We integrated single-nucleus ATAC-seq and RNA-seq data from 71 donors (36 affected by schizophrenia) with GWAS summary statistics to identify TF motifs whose binding affinities are altered by schizophrenia-associated SNPs. We found that risk alleles of schizophrenia-associated SNPs disrupt and enhance TF binding. Furthermore, we demonstrated that disrupted TF motifs can lead to altered expression of target genes, including NAGA in excitatory neurons and SNX19 in protoplasmic astrocytes. These genes have been previously implicated in schizophrenia and our study provides a mechanism for their dysregulation through altered TF binding. Our findings highlight the importance of considering cell type-specific effects and provide a genome-wide map of TF motif disruptions in schizophrenia, offering insights into the regulatory mechanisms underlying disease risk. These findings may inform the development of novel therapeutic strategies targeting specific regulatory mechanisms.

Indexed as

Cerebral CortexGene Expression RegulationPolymorphism, Single NucleotideSchizophreniaTranscription FactorsBinding SitesGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansNeuronsProtein BindingTranscription FactorsCell typeGenetic variantsMotif alterationsOrbitofrontal cortexSchizophreniaTranscription factor binding

Identifiers

PMID41863598
PMCPMC13046938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.